Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis

Table 2

Characteristics of patients and hazard ratios (HR) (95% confidence interval [95%CI]) of mitotane in multivariate Cox regression model fitted for time of recurrence-free survival (RFS) and overall survival (OS), adjusted by age, gender, stage, positive surgical margins (PSMs), functional status and/or adjuvant radiation, etc.

Reference	Year	Total No.	Age/y	Male/%	Stage IV/%	PSMs/%	Function/%	Radiation/%	Mitotane	RFS/HR(95%CI)	OS /HR(95%CI)
Berruti [16]	2017	92	43	32	11	-	45	0	47	1/2.98(1.75-5.09)	1/2.03(1.17-3.51)
Postlewait [27]	2016	169	51	39	31	31	43	10	56	1.4(0.8-2.4)	0.7(0.3-1.5)
Berruti [28]	2014	524	45	39	0	0	52	-	251	0.66(0.53-0.83)	0.82(0.60-1.10)
Grubbs [29]	2010	215	46	35	4	27	55	-	19	1/1.96(1.07-3.61)	1/1.58(0.75-3.31)
Fassnacht [30]	2010	149	48	35	0	9	-	9	35	0.58(0.29-1.15)	0.38(0.12-1.28)

a Median or mean age of total population.
b Local advanced cases without distant metastasis.
c (R1+R2) / (R0+R1+R2) (R0 denotes microscopically negative margin; R1 denotes microscopically positive margin; R2 denotes grossly positive margin) in spite of Rx or data loss.
d Number of patients who received mitotane.
e HR of mitotane relative to nonmitotane. When a study provided HR of no mitotane relative to mitotane, it was recorded as 1/HR.